NCT06625177View on ClinicalTrials.gov

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

May 9, 2026

Study Completion Date

June 5, 2027

Conditions
Vitiligo
Interventions
DRUG

TEV-53408

TEV-53408 injection administered subcutaneously

Trial Locations (12)

33025

RECRUITING

Teva Investigational Site 12049, Miramar

40421

ACTIVE_NOT_RECRUITING

Teva Investigational Site 12053, Louisville

48187

RECRUITING

Teva Investigational Site 12048, Canton

60614

ACTIVE_NOT_RECRUITING

Teva Investigational Site 12047, Chicago

71913

ACTIVE_NOT_RECRUITING

Teva Investigational Site 12052, Hot Springs

75230

RECRUITING

Teva Investigational Site 12045, Dallas

77598

RECRUITING

Teva Investigational Site 12057, Webster

84095

ACTIVE_NOT_RECRUITING

Teva Investigational Site 12055, South Jordan

85260

TERMINATED

Teva Investigational Site 12043, Scottsdale

91101

RECRUITING

Teva Investigational Site 12046, Pasadena

94538

RECRUITING

Teva Investigational Site 12044, Fremont

97210

RECRUITING

Teva Investigational Site 12054, Portland

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D LLC

INDUSTRY